TCT-193 Zotarolimus eluting stent compared with GENOUS stent in patients with ST-elevation myocardial infarction undergoing primary PCI
Author + information
Background
The purpose of this study was to compare the outcome between the Genous endothelial progenitor cell capturing stent, aimed to fasten stent endothelialization and the zotarolimus-eluting Resolute stent (ZES), which reduces neointimal thickening, in ST-segment elevation myocardial infarction (STEMI) patients.
Methods
This study included 670 propensity score matched pairs of STEMI patients treated by either Genous stent or ZES, between 2007 and 2014. The primary endpoint was target lesion failure (TLF) – a composite of death from cardiac causes, myocardial infarction (not clearly attributable to a non-target vessel), or clinically indicated target-lesion revascularization at 1 month and 1 year follow-up. Stent thrombosis (ST), according to the Academic Research Consortium criteria, was also evaluated.
Results
The incidence of TLF at 1 month was 3.8% in the ZES group vs. 7.1% in the Genous group, (hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.35–0.95; p=0.01). Definite stent thrombosis rate was numerically higher in the GENOUS group but this was not statistically significant (2.1% vs 1.0%, p=0.12).
Conclusion
In STEMI patients, implantation of a ZES resulted in a significantly lower rate of TLF compared with the Genous stent at short term follow-up, mainly driven by a higher incidence of repeat revascularization in patients treated with the Genous stent. Stentthrombosis was numerically lower in the ZES group but this difference was not significant. The results of the 1 year follow-up are not complete yet and will be presented at the meeting.
Categories
CORONARY: Stents: Drug-Eluting
